107 related articles for article (PubMed ID: 30158361)
1. The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year's bone mineral density change.
Chen CY; Chen ST; Huang BY; Hwang JS; Lin JD; Liu FH
Endocr J; 2018 Nov; 65(11):1101-1109. PubMed ID: 30158361
[TBL] [Abstract][Full Text] [Related]
2. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
3. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.
Baldini M; Gallazzi M; Orsatti A; Fossati S; Leonardi P; Cantalamessa L
J Intern Med; 2002 May; 251(5):407-14. PubMed ID: 11982740
[TBL] [Abstract][Full Text] [Related]
4. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
5. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
7. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.
Lima N; Knobel M; Cavaliere H; Sztejnsznajd C; Tomimori E; Medeiros-Neto G
Thyroid; 1997 Oct; 7(5):691-7. PubMed ID: 9349571
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
9. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
[TBL] [Abstract][Full Text] [Related]
10. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
[TBL] [Abstract][Full Text] [Related]
11. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
[TBL] [Abstract][Full Text] [Related]
12. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
13. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
14. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
16. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
17. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of L-thyroxine (L-T4) therapy on the volume of the thyroid gland and nodules in patients with euthyroid nodular goiter (ENG)].
Diacinti D; Salabè GB; Olivieri A; D'Erasmo E; Tomei E; Lotz-Salabè H; De Martinis C
Minerva Med; 1992 Nov; 83(11):745-51. PubMed ID: 1461545
[TBL] [Abstract][Full Text] [Related]
19. The effect of long-term thyroxine on bone mineral density and serum cholesterol.
Fowler PB; McIvor J; Sykes L; Macrae KD
J R Coll Physicians Lond; 1996; 30(6):527-32. PubMed ID: 8961207
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter.
Wesche MF; Tiel-V Buul MM; Lips P; Smits NJ; Wiersinga WM
J Clin Endocrinol Metab; 2001 Mar; 86(3):998-1005. PubMed ID: 11238476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
